An interventional study of Usual Oxygen During 6-Minute Walk Test and Supplemental Oxygen During 6-Minute Walk Test in Chronic Respiratory Failure, Hypoxemia and Chronic Obstructive Pulmonary Disease (COPD), sponsored by Istituti Clinici Scientifici Maugeri SpA. Recruiting at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Istituti Clinici Scientifici Maugeri SpA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Hypoxia with a site in Italy — 4 open to participants now, 5 under way, none of them phase 3. Hypoxia · Italy.
Among the 26 studies in Hypoxia with a site in Italy, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 25th registered.
1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.
Browse Hypoxia studies →4 of the 26 studies in Hypoxia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18–75 · Women only
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–99
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+ · Women only
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 114 is above the median of 45 across 771 interventional studies indexed under Hypoxia.
Median enrollment 48 across the 19 interventional studies, 400 across the 7 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Istituti Clinici Scientifici Maugeri SpA is the lead sponsor of 128 studies on the registry; 52 are open to participants now.
Istituti Clinici Scientifici Maugeri SpA has 2 studies filed under Hypoxia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies in Hypoxia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective easiness of performance, in a cohort of subjects hospitalized in specialized pulmonary rehabilitation centers with a diagnosis of chronic respiratory failure and/or exertional hypoxemia due to chronic obstructive pulmonary disease or interstitial lung disease.
Researchers will compare the walking performance during 6-minute walk test performed with the liters of oxygen administered as prescribed at rest (for patients with chronic respiratory failure) or in room air (for patients with exertional hypoxemia only), to the performance during a 6-minute walk test performed with the double the flow rate prescribed at rest, or with 2 L/min for patients with exertional hypoxemia only. The two tests will be performed in random order, at least 3 hours apart and no later than 24 hours apart from each other.
The main outcome will be the difference between the distance walked in the two 6-minute walk test in the two conditions. Furthermore, will be also collected and compared: the oxygen saturation and heart rate every minute, the initial and final dyspnea and fatigue, as assessed by Borg scale, and the easiness of performance through a dedicated questionnaire. The estimated sample size will be 114 patients.
This study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure.
Although supplemental oxygen enhances acute exercise performance in COPD, its long-term impact on quality of life and mortality remains unproven. Current guidelines suggest treating exertional desaturation (SpO2\<90%), but the lack of standardized titration protocols, particularly using the 6MWT, limits clinical consistency. While many patients with chronic respiratory failure (CRF) receive dual-level oxygen prescriptions (rest vs. exercise), it is unclear if this approach yields significant functional gains. Therefore, In light of these considerations, the present multicenter crossover study aims to describe the effect of adding a therapeutic dose of exertional oxygen therapy in terms of:
As secondary aim, the study will also evaluate any difference in the response among different diseases.
This study will be conducted on subjects with chronic respiratory diseases admitted to the Pulmonary Units of the ICS Maugeri , for rehabilitation will be evaluated for inclusion in the protocol. After approval of the project by the Ethical Committee, those who meet the following criteria at the time of discharge will be enrolled in the study.
We will enroll 3 different groups of patients:
A) Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with EH, with an exertional oxygen prescription and a PaO2 > 60mmHg breathing room air at rest; B) Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) with Chronic Respiratory Failure, with a daytime long-term oxygen therapy (LTOT) prescription and a PaO2 \< 60mmHg breathing room air at rest; C) Diagnosis of Interstitial Lung Disease (ILD) with Chronic Respiratory Failure with a daytime long-term oxygen therapy (LTOT) and a PaO2 \< 60mmHg breathing room air at rest.
All patients have to be in a clinically stable condition for at least one month with optimized therapy during hospitalization.
Exclusion criteria will include: presence of lung diseases other than COPD or ILD; patients requiring a resting oxygen flow rate greater than 6 L/min; patients with orthopedic, cognitive, or neurological conditions that may affect test outcomes; patients with recent cardiovascular or cerebrovascular events within the previous three months; and cognitive impairment evaluated by Mini-Mental State Examination (MMSE) score as \< 25.
With a cross-over multicenter randomized design, at the time of discharge, all patients will perform two 6-Minute Walking Tests in a random order under the following conditions:
The 6MWT will be performed, according to the ATS/ERS guidelines, along a flat corridor of at least 20 meters. Each patient will receive standardized pre-test instructions and verbal encouragement at every minute during the test. The two tests will be performed at least 3 hours apart and no later than 24 hours apart from each other. All patients will perform the tests using nasal prongs and a stroller (liquid oxygen). The stroller will be either held by the patients or transported via a backpack or rollator. When patients perform the test in room air, they will carry the stroller with no oxygen supply.
The following anthropometric and clinical measures will be collected at admission: age, BMI, diagnosis, blood gas analysis (PaO2, PaCO2, pH) at rest breathing room air, time from diagnosis, time from first oxygen prescription, spirometry (FEV1, FVC, IT, RV).
The following data will be recorded during the two 6MWT tests:
To evaluate the patient-reported easiness of performance at the end of the second test, a dedicated questionnaire will be administered.
The "oxygen response" will be the primary outcome, defined as the 6-min walk distance using supplemental oxygen (O2PLUS) minus the 6-min walk distance using O2 quantity prescribed at rest (O2REST).
The sample size calculation was done about previous literature study data on 6-minute walk distance, assuming a two-sided α level of 0.01 and a power of 90% and including a 15% dropout rate, according to the diseases: in GROUP A, a sample size of at least 41 patients will be necessary to detect a clinically relevant difference of 28 meters in 6MWD (SD 44); in GROUP B, a sample size of at least 22 patients will be necessary to detect a clinically relevant difference of 37 meters in 6MWD (SD 40); in GROUP C, a sample size of at least 50 patients will be necessary to detect a clinically relevant difference in 6MWD of 13 meters (SD 30) between the two conditions.
The data will be analyzed using STATA 12 (StataCorp, LLC) and GraphPad Prism 8 (GraphPad Software, Boston, MA, US). Baseline characteristics and outcomes will be summarized with descriptive statistics. Continuous variables will be expressed as mean ± standard deviation (SD) or median (interquartile range, IQR) if not normally distributed. Categorical variables will be presented as percentages.
Patients who increased their 6MWD by at least 30 meters due to O2_suppl. were defined as "oxygen responders". A statistical comparison between tests for paired data will be performed using paired t-tests if the variables are normally distributed, or the Wilcoxon signed-rank test if the variables are not normally distributed. The analysis will be conducted within groups, and an additional analysis will be performed by pooling the data into a single group. Furthermore, a linear regression analysis will be carried out to assess whether the changes induced by oxygen administration are associated with baseline clinical or anthropometric factors. Differences in all recorded parameters between the two conditions, both in terms of delta (change) and kinetics, will be also calculated. Statistical significance will be set at p \< 0.05.
We expect to observe an improvement gap in terms of performance or symptoms in a high proportion of patients when tested under hyperoxia. However, the proportion of patients who respond to the hyperoxic stimulus, as well as the characteristics of this phenotype, remain unclear to date.
This study will provide some basis for a more accurate prescription of exercise-related oxygen therapy, offering insights into the phenotype of patients who may derive the greatest benefit from this intervention. It will also stimulate discussion regarding the optimal timing and dosing of oxygen administration during exertion in patients with respiratory failure. In practice, it will help to characterize the acute effects of oxygen administration during exertion, considering the benefits in terms of physical performance and symptom relief. Furthermore, it will support reflections on the economic and social impact of oxygen prescription, initiating a discussion on the appropriate dosing strategy for exertional oxygen therapy.
Condition or disease:
Intervention/treatment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants perform the 6-minute walk test with standard oxygen flow (or room air for participants with exertional hypoxemia only). This arm represents the standard condition for comparison. The test may be administered as first or second test, in a random order, according to the crossover design.
Other: Usual Oxygen During 6-Minute Walk Test
All participants perform the 6-minute walk test using a higher oxygen flow during exercise to evaluate the effects of supplemental oxygen on walking performance and symptoms. The test may be administered as first or second test, in a random order, according to the crossover design.
Other: Supplemental Oxygen During 6-Minute Walk Test
Participants perform the 6-minute walk test using the oxygen flow prescribed at rest for chronic respiratory failure, or room air for participants with exertional hypoxemia only. Oxygen is delivered through nasal cannula using standard equipment. Walking distance, oxygen saturation, heart rate, and symptoms are recorded during the test.
Participants perform the 6-minute walk test using supplemental oxygen during exercise. Oxygen flow is set at double the resting prescription for participants with chronic respiratory failure, or at two liters per minute for participants with exertional hypoxemia. Oxygen is delivered through nasal cannula using standard equipment. Walking distance, oxygen saturation, heart rate, and symptoms are recorded during the test.
Change in 6-Minute Walk Distance With Supplemental Oxygen
This outcome measures the difference in walking distance during the 6-minute walk test when participants use supplemental oxygen (O2PLUS) compared to their usual oxygen setting or room air (O2REST). The change is calculated as the distance walked with supplemental oxygen minus the distance walked with usual oxygen or room air. This outcome reflects the short-term effect of supplemental oxygen on exercise performance.
Time frame: Within 24 hours (during two 6-minute walk tests performed on the same day)
Oxygen Saturation During the 6-Minute Walk Test
This outcome measures oxygen saturation levels recorded during the 6-minute walk test when participants walk with supplemental oxygen and when they walk with their usual oxygen setting or room air. Oxygen saturation is recorded every minute during the test to evaluate changes in blood oxygen levels during walking.
Time frame: During each 6-minute walk test
Heart Rate During the 6-Minute Walk Test
This outcome measures heart rate recorded during the 6-minute walk test under both oxygen conditions. Heart rate is monitored every minute during walking to assess the cardiovascular response to exercise with and without supplemental oxygen.
Time frame: During each 6-minute walk test
Dyspnea Before and After the 6-Minute Walk Test
This outcome measures the level of dyspnea reported by participants using the Borg Dyspnea Scale before the test, immediately after the test, and three minutes after recovery. Results are compared between walking with supplemental oxygen and walking with usual oxygen or room air.
Time frame: Before the test, immediately after the test, and 3 minutes after recovery
Muscles Fatigue Before and After the 6-Minute Walk Test
This outcome measures perceived fatigue using the Borg Fatigue Scale before the test, immediately after the test, and three minutes after recovery. Fatigue scores are compared between the two oxygen conditions.
Time frame: Before the test, immediately after the test, and 3 minutes after recovery
Blood Pressure Before and After the 6-Minute Walk Test
This outcome measures systolic and diastolic blood pressure assessed before and immediately after the 6-minute walk test under both oxygen conditions to monitor physiological response to exercise.
Time frame: Before and immediately after each 6-minute walk test
Participant-Reported Perception of Walking Performance
This outcome measures participants' subjective perception of their walking performance after completing both 6-minute walk tests. Participants rate perceived differences in shortness of breath, fatigue, and overall ability to walk between the two tests using a structured dedicated questionnaire.
Time frame: Immediately after completion of the second 6-minute walk test
Plan to share: No
Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.
Of 324 non-industry interventional studies with no phase under Hypoxia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 21 months is above that.
Counting every sponsor, half of 354 studies reached it within 12 months; a quarter within 3 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituti Clinici Scientifici Maugeri SpA →